Meeting
2022 ASCO Annual Meeting
Treatment patterns and outcomes in ALK or ROS1 altered NSCLC: An ATOMIC Registry Study.
Authors
Melina Elpi Marmarelis
University of Pennsylvania, Philadelphia, PA
Melina Elpi Marmarelis , Connor B. Grady , Geoffrey Liu , Devalben Patel , Stephen V. Liu , Gabriela Liliana Bravo Montenegro , Tejas Patil , Jorge J. Nieva , Amanda Herrmann , Kristen Marrone , Vincent K. Lam , Fangdi Sun , Jonathan Dowell , Vamsidhar Velcheti , Matthew Nguyen , Kelsey Leigh Miller , Wade Thomas Iams , Wei-Ting Hwang , D. Ross Camidge , Charu Aggarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9077)
DOI
10.1200/JCO.2022.40.16_suppl.9077
Abstract #
9077
Poster Bd #
64
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer.
First Author: Jessica Jiyeong Lin
Poster
2020 ASCO Virtual Scientific Program
Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.
First Author: Minsuk Kwon
Poster
2023 ASCO Annual Meeting
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.
First Author: Kaushal Parikh
Poster
2023 ASCO Annual Meeting
Mechanisms of resistance to tyrosine kinase inhibitor treatments in patients with ROS1 fusion-positive non-small cell lung cancer.
First Author: Jialei Wang